The global cell lysis market size is projected to reach USD 4.1 billion by 2026 from USD 2.9 billion in 2020, at a CAGR 7.2% from 2021 to 2026. The growth of this market is driven by increasing government funding for research, high prevalence of diseases, and growing focus on personalized medicines
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=260138321
Opportunity: Growing opportunity in emerging markets
Emerging countries such as China, Brazil, Mexico, and India present significant opportunities for players in the cell lysis market. The major reasons for this are the increasing prevalence of chronic diseases, improvements in infrastructure facilities for research, and favorable legislation for cell-based research in emerging countries. Due to this, key industry players strengthen their presence in emerging countries like China by establishing new facilities and R&D and innovation centers in the region.
Challenge: Survival of small players and new entrants
The survival of small players and new entrants in the cell lysis market is a significant challenge. Huge investments are required for the R&D and launch of innovative products in the market. Thus, to remain competitive in the market, companies have to invest heavily. Moreover, market players have to reduce operational costs to successfully survive in the market, which is very difficult for small players and new entrants.
The cell lysis market is highly consolidated and is dominated by various players. The major players operating in this market are Thermo Fisher Scientific (US), Merck KGaA (Germany), Becton, Dickinson and Company (US), Danaher Corporation (US), Bio-Rad Laboratories (US), Miltenyi Biotec (Germany), QIAGEN (Netherlands), Roche Diagnostics (Switzerland), Agilent Technologies Inc. (US), NZYTech Lda (Portugal), Labfreez Instruments Group Co., Limited (China), G-Biosciences (US), Covaris (US), Claremont BioSolutions LLC (US), Microfluidics International Corporation (US), Parr Instrument Company (US), BioVision Inc.(US), and Norgen Biotek (Canada).
Thermo Fisher Scientific (US)
Thermo Fisher Scientifc (US) held the leading position in the cell lysis market in 2020. Thermo Fisher offers an exhaustive product portfolio consisting of various cell lysis products, such as reagents, kits, and media. The company believes in both organic and inorganic growth for enhancing its market position such collaboration, acquisition and expansion. For instance, in 2020, Thermo Fisher Scientific entered collaboration with Northeastern University To advance analytical capabilities and accelerate innovation across the biopharmaceutical industry in personalized medicine, monoclonal antibodies, and gene and cell therapies. Furthermore, the company is innovation-centric and invests heavily in R&D to maintain its market share..
Request Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=260138321
North America accounted for the largest share of the cell lysis inudstry.
Based on the region, the cell lysis market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2020, North America accounted for the largest share of the global market. The large share of North America can be attributed to factors such as growing stem cell and cancer research activities and the expanding biotechnology & pharmaceutical industries
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com
